Filing Details
Aardvark Therapeutics, Inc. (NASDAQ:AARD) filed a Form 8-K with the Securities and Exchange Commission on October 23, 2026, disclosing a material event.
8k filedNASDAQ:AARD
Aardvark Therapeutics, Inc. (AARD) Reports Material Event to SEC
Aardvark Therapeutics, Inc. (NASDAQ:AARD) filed a Form 8-K with the Securities and Exchange Commission on October 23, 2026, disclosing a material event.
At publication ·
What changed
Aardvark Therapeutics, Inc. (NASDAQ:AARD) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Aardvark Therapeutics filed a Form 8-K on October 23, 2026, disclosing a material event that shareholders should monitor.
- The company's stock trades at $1.39 with a market capitalization of $271.9 million.
- Form 8-K filings report significant events such as leadership changes, material agreements, acquisitions, or asset sales between regular reports.
Market Context
Aardvark Therapeutics, Inc.'s stock currently trades at $1.39 with a market capitalization of $271.9M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Aardvark Therapeutics, Inc.'s stock.
All SEC filings for Aardvark Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AARD Stock Page
Frequently Asked Questions
Where can I read AARD's SEC filings?
Browse all filings on our AARD SEC filings page.
What types of SEC filings does Aardvark Therapeutics, Inc. file?
Public companies like Aardvark Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.